DivestmentApr 23, 2026, 09:07 AM
Cumberland Pharma to Divest Commercial Products to Apotex for $100M
AI Summary
Cumberland Pharmaceuticals Inc. has entered into a strategic transaction to integrate its commercial products with an affiliate of Apotex Inc. Apotex will acquire several FDA-approved products, including Acetadote and Caldolor, for $100 million. Cumberland will retain its Cumberland Emerging Technologies assets and ifetroban product candidates, intending to focus on their development. The deal, unanimously approved by Cumberland's board, is subject to shareholder approval and other customary closing conditions.
Key Highlights
- Cumberland Pharmaceuticals Inc. entered a strategic transaction with an Apotex Inc. affiliate.
- Apotex will acquire specified FDA-approved products for $100,000,000.
- Products include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ.
- Cumberland will retain assets related to Cumberland Emerging Technologies and ifetroban product candidates.
- The transaction requires shareholder approval and has been unanimously approved by Cumberland's board.